# Nicolas Belmar

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nicolas-belmar/

## Facts

| Field | Value |
| --- | --- |
| Citations | 235 |
| Field | Diabetes Treatment and Management |
| h-index | 6 |
| i10-index | 3 |
| Last Known Institution | Novo Nordisk (Denmark) |
| OpenAlex ID | https://openalex.org/A5113262208 |
| Works | 22 |

## Researcher papers

- [Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial](https://scholariq.org/papers/effects-of-semaglutide-with-and-without-concomitant-sglt2-inhibitor-use-in/)
- [Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis](https://scholariq.org/papers/effects-of-semaglutide-with-or-without-concomitant-mineralocorticoid-receptor/)
- [Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease](https://scholariq.org/papers/rationale-design-and-baseline-characteristics-of-remodel-a-mechanism-of-action/)
- [Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6](https://scholariq.org/papers/cardiovascular-metabolic-and-safety-outcomes-with-semaglutide-by-baseline-age/)
- [REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide](https://scholariq.org/papers/remodeling-mechanistic-trials-for-kidney-disease-a-multimodal-tissue-centered/)
- [Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial](https://scholariq.org/papers/impact-of-oral-semaglutide-on-kidney-outcomes-in-people-with-type-2-diabetes/)
- [Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial](https://scholariq.org/papers/mechanistic-effects-of-semaglutide-on-kidney-disease-in-type-2-diabetes-the/)
- [1971-LB: Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial](https://scholariq.org/papers/1971-lb-impact-of-semaglutide-on-kidney-cardiovascular-and-mortality-outcomes-by/)
- [Trial Design and Baseline Characteristics from REMODEL: A Mechanistic Study of Semaglutide vs. Placebo in People with Type 2 Diabetes and CKD](https://scholariq.org/papers/trial-design-and-baseline-characteristics-from-remodel-a-mechanistic-study-of/)
- [Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Pre-Specified Secondary Analysis](https://scholariq.org/papers/effects-of-semaglutide-with-or-without-concomitant-mineralocorticoid-receptor-2/)
- [Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial](https://scholariq.org/papers/effect-of-semaglutide-on-covid-19-and-other-infections-an-analysis-from-the-flow/)
- [Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease](https://scholariq.org/papers/kidney-and-survival-benefits-of-semaglutide-in-diabetes-with-chronic-kidney/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)

## Researcher university

- [Novo Nordisk (Denmark)](https://scholariq.org/institutions/novo-nordisk-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.